Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$50.80

1.29 (2.61%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23

Portola: FDA extends review period for PAS for Bevyxxa

Portola Pharmaceuticals announced that the U.S. Food and Drug Administration has extended the review period for the company's Prior Approval Supplement for Bevyxxa to allow the agency time to review the entire submission. The FDA informed the company today that it will respond to the PAS request to change the current manufacturing release specification within the standard 60-day extension period. No additional information was requested at this time. The new action date is January 30, 2018. "As we communicated earlier this month, we've made good progress with the FDA and have established an agreement in principle on the change to our product release specification that would allow for the release and distribution of current product inventory. We also noted that the agency might need additional time to review our submission," said Bill Lis, chief executive officer of Portola. "While the FDA completes its review, the momentum within the medical community is building. We continue our commercial and medical education activities in anticipation of a potential launch by February 2018, and remain committed to getting Bevyxxa to patients who may benefit from this important and potentially life-saving new therapy."

  • 02

    Feb

PTLA Portola Pharmaceuticals
$50.80

1.29 (2.61%)

09/19/17
OPCO
09/19/17
NO CHANGE
OPCO
Outperform
Portola Pharmaceuticals mentioned positively at Oppenheimer
09/19/17
OPCO
09/19/17
NO CHANGE
OPCO
Outperform
Portola selloff today based on 'stale' guidelines draft, says Oppenheimer
Oppenheimer analyst Jay Olson views the selloff today in shares of Portola Pharmaceuticals as "off-target." The decline is based on the rehashing of draft guidelines that were available for public comment from July 24 to August 25, Olson tells investors in an afternoon research note titled "Stale Draft Recommendations for VTE Mysteriously Resurface." The draft references the August 2016 New England Journal of Medicine article for Portola's Bevyxxa versus Lovenox in cohort one on the primary efficacy outcome, the analyst notes. He expects revised final guidelines to be published by year-end and keeps an Outperform rating on Portola. The stock in afternoon trading is down 7% to $52.52 after STAT News said the company's blood thinner launch could be complicated by the guidelines.
09/19/17
SBSH
09/19/17
NO CHANGE
SBSH
Buy
Portola selloff on draft guidance 'red herring' a buying opportunity, says Citi
Citi analyst Yigal Nochomovitz attributes today's selloff in Portola Pharmaceuticals shares to controversy over the fact that the American Society of Hematology's draft recommendations argue against extended prophylaxis for VTE in acute medically ill patients. However, he points out that the document lacks any mention of Bevyxxa's status as FDA approved, which suggests the draft "needs to be revisited and/or is stale." The analyst concludes the draft was made prior to Bevyxxa approval and before the "many, many downstream publications" Portola has generated since then. Nochomovitz, who recommends investors buy the dip, keeps a Buy rating on Portola, which is down 7% in afternoon trading.
09/20/17
FBCO
09/20/17
NO CHANGE
Target $70
FBCO
Outperform
Portola Pharmaceuticals selloff surprising, says Credit Suisse
Credit Suisse analyst Vamil Divan says he is surprised that Portola shares sold off about 8% on concerns that extended duration VTE prophylaxis for acute medically ill patients is not recommended in draft guidelines from the American Society of Hematology. The analyst believes the negative reaction is unwarranted, and reiterates an Outperform rating and $70 price target on the shares.

TODAY'S FREE FLY STORIES

TSM

TSMC

$39.30

-0.07 (-0.18%)

07:57
12/13/17
12/13
07:57
12/13/17
07:57
Periodicals
TSMC chairman says HPC chip demand remains strong, DigiTimes reports »

TSMC (TSM) chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$26.33

-0.25 (-0.94%)

07:56
12/13/17
12/13
07:56
12/13/17
07:56
Conference/Events
Kroger management to meet with Deutsche Bank »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ST

Sensata

$51.66

3.76 (7.85%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Recommendations
Sensata analyst commentary  »

Sensata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$15.70

-0.17 (-1.07%)

, FTR

Frontier Communications

$10.05

-0.01 (-0.10%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Recommendations
CenturyLink, Frontier Communications, Windstream analyst commentary  »

Morgan Stanley says…

CTL

CenturyLink

$15.70

-0.17 (-1.07%)

FTR

Frontier Communications

$10.05

-0.01 (-0.10%)

WIN

Windstream

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$56.40

-0.25 (-0.44%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Conference/Events
Unum Group to host investor day »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HON

Honeywell

$153.74

0.53 (0.35%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Conference/Events
Honeywell to hold a conference call »

Management provides 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

JLL

Jones Lang LaSalle

$149.76

0.56 (0.38%)

07:55
12/13/17
12/13
07:55
12/13/17
07:55
Conference/Events
Jones Lang LaSalle to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

AAPL

Apple

$171.70

-0.97 (-0.56%)

07:52
12/13/17
12/13
07:52
12/13/17
07:52
Periodicals
Apple hires Matthys, Grazier for business affairs on content team, Variety says »

Apple has hired Philip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$52.69

0.61 (1.17%)

07:51
12/13/17
12/13
07:51
12/13/17
07:51
Syndicate
TD Ameritrade 27.7M share Spot Secondary priced at $51.50 »

Goldman Sachs acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBS

HubSpot

$82.70

-0.7 (-0.84%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Conference/Events
HubSpot management to meet with Needham »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

VZ

Verizon

$53.19

1.35 (2.60%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Conference/Events
Verizon management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CRL

Charles River

$104.57

0.67 (0.64%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Initiation
Charles River initiated  »

Charles River initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAY

Verifone

$18.47

0.28 (1.54%)

07:50
12/13/17
12/13
07:50
12/13/17
07:50
Technical Analysis
Technical View: Verifone falls after earnings and outlook disappoint »

In premarket trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

FRED

Fred's

$3.77

-0.19 (-4.80%)

07:49
12/13/17
12/13
07:49
12/13/17
07:49
Conference/Events
Fred's management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NICE

Nice

$87.71

0.03 (0.03%)

07:47
12/13/17
12/13
07:47
12/13/17
07:47
Recommendations
Nice analyst commentary  »

Nice price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PM

Philip Morris

$107.30

1.26 (1.19%)

07:46
12/13/17
12/13
07:46
12/13/17
07:46
Recommendations
Philip Morris analyst commentary  »

Philip Morris named a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$60.98

1.64 (2.76%)

07:45
12/13/17
12/13
07:45
12/13/17
07:45
Recommendations
Hexcel analyst commentary  »

Hexcel investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$73.62

0.33 (0.45%)

, VNTV

Vantiv

$74.79

0.17 (0.23%)

07:42
12/13/17
12/13
07:42
12/13/17
07:42
Recommendations
PayPal, Vantiv, ADP, Paychex, Amazon.com analyst commentary  »

Wedbush bullish on…

PYPL

PayPal

$73.62

0.33 (0.45%)

VNTV

Vantiv

$74.79

0.17 (0.23%)

ADP

ADP

$117.05

-0.77 (-0.65%)

PAYX

Paychex

$68.71

-0.31 (-0.45%)

AMZN

Amazon.com

$1,165.08

-3.84 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 21

    Dec

  • 08

    Jan

  • 18

    Mar

AEE

Ameren

$61.36

-1.8425 (-2.92%)

07:42
12/13/17
12/13
07:42
12/13/17
07:42
Downgrade
Ameren rating change  »

Ameren cut to Underweight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$171.70

-0.97 (-0.56%)

07:41
12/13/17
12/13
07:41
12/13/17
07:41
Periodicals
Apple SVP Phil Schiller talks Face ID, HomePod delay, T3 reports »

Apple SVP of worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$190.95

-10.85 (-5.38%)

07:41
12/13/17
12/13
07:41
12/13/17
07:41
Downgrade
bluebird bio rating change  »

bluebird bio downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PRLB

Proto Labs

$95.85

1.85 (1.97%)

07:40
12/13/17
12/13
07:40
12/13/17
07:40
Earnings
Proto Labs guides initial FY18 EPS $2.40-$2.60, consensus $2.51 »

Guides initial FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$36.88

1.08 (3.02%)

07:39
12/13/17
12/13
07:39
12/13/17
07:39
Recommendations
Trinity Industries analyst commentary  »

Trinity Industries price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRLB

Proto Labs

$95.85

1.85 (1.97%)

07:38
12/13/17
12/13
07:38
12/13/17
07:38
Earnings
Proto Labs raises Q4 EPS view to 53c-59c from 52c-58c, consensus 56c »

Raises Q4 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEP

American Electric

$76.02

-1.06 (-1.38%)

07:38
12/13/17
12/13
07:38
12/13/17
07:38
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.